NARR Inhibitors
Chemical inhibitors of NARR protein can exert their inhibitory action through various mechanisms, targeting different signaling pathways and molecular processes that are essential for NARR protein functionality. Wortmannin and LY294002 are inhibitors of phosphoinositide 3-kinases (PI3Ks), key enzymes that regulate a broad range of cellular functions by initiating signaling cascades that can lead to the activation of the NARR protein. By inhibiting PI3K, these chemicals prevent the phosphorylation and subsequent activation of downstream targets such as AKT, which are crucial for the function of NARR protein. Rapamycin, targeting the mTOR pathway, can disrupt NARR protein function by interfering with one of the core components of cell growth and metabolism that may regulate the activity of NARR protein.
Furthermore, SB203580, which inhibits p38 MAPK, can affect the NARR protein by altering the cell's response to stress and cytokines, thereby possibly affecting cell differentiation and survival pathways that involve NARR protein. PD98059 and U0126 are inhibitors of MEK1/2, which are upstream of the ERK pathway, a pathway that can modulate various cellular processes that include the activation of NARR protein. By preventing the activation of MEK, these inhibitors can prevent the phosphorylation of ERK, which is potentially involved in the regulation of the NARR protein. SP600125, a JNK inhibitor, can also suppress NARR protein activity by altering stress response and apoptotic signaling pathways. PP2 and Dasatinib, as Src family tyrosine kinase inhibitors, can disrupt multiple cellular signaling pathways that might be crucial for the activation or function of the NARR protein. Lastly, Bortezomib, by inhibiting the proteasome, can affect the turnover of various proteins that regulate the NARR protein, leading to changes in its activity. Sorafenib and Imatinib, by targeting multiple kinases, can alter the cellular signaling landscape and thereby influence the functional state of the NARR protein. These chemical inhibitors, through their diverse mechanisms, can collectively modulate the activity and regulation of the NARR protein within cellular signaling networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3Ks), which are upstream regulators of several signaling pathways. Inhibition of PI3K can prevent the activation of downstream targets such as AKT, which might be necessary for NARR protein function, thus leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another well-known inhibitor of PI3K. By blocking PI3K activity, LY294002 can disrupt downstream signaling pathways that are critical for the NARR protein's activity, leading to its inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is part of the PI3K/AKT/mTOR pathway, a potential regulator of NARR protein function. This inhibition can disrupt the signaling required for NARR protein activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which is involved in cell differentiation, apoptosis, and autophagy pathways. By inhibiting p38 MAPK, SB203580 could interfere with cellular pathways essential for NARR protein function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of the ERK pathway. Since the ERK pathway can regulate various cellular functions including growth and survival, inhibition by PD98059 could lead to suppression of NARR protein activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is a part of the MAPK family. JNK pathway is implicated in controlling numerous cellular processes, and its inhibition may result in the suppression of NARR protein function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2, which are part of the MAPK/ERK pathway. By inhibiting these kinases, U0126 can block the phosphorylation and activation of ERK, potentially inhibiting cellular processes that NARR protein relies on. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases can interact with multiple signaling pathways that could be essential for NARR protein activity, and their inhibition by PP2 could result in functional inhibition of NARR protein. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases and BCR-ABL. Its inhibition of these kinases could disrupt signaling pathways that are necessary for the full function of the NARR protein. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can affect the degradation of regulatory proteins within the cell. By inhibiting the proteasome, Bortezomib might prevent the degradation of proteins that negatively regulate NARR protein, thus leading to its functional inhibition. | ||||||